Veliparib API Manufacturers & Suppliers
0 verified results
All Veliparib data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Veliparib | CAS No: 912444-00-9 | GMP-certified suppliers
A medication that inhibits PARP enzymes to support cancer treatment by disrupting DNA repair in tumor cells, primarily investigated for use as an antineoplastic agent.
Therapeutic categories
Product Snapshot
- Veliparib is an oral small molecule inhibitor
- It is primarily investigated for use in oncology indications
- Veliparib currently holds investigational status without approved market authorizations
Clinical Overview
Although specific clinical indications for Veliparib have not been fully established, its mechanism of action aligns with the inhibition of PARP enzymes. PARP enzymes play a critical role in the repair of single-strand DNA breaks through the base excision repair pathway. By inhibiting PARP, Veliparib interferes with DNA repair mechanisms in cancer cells, leading to the accumulation of DNA damage and potential cell death, particularly in tumor cells deficient in homologous recombination repair pathways.
Key pharmacokinetic parameters of Veliparib, including absorption, distribution, metabolism, and elimination, have been the subject of clinical investigation. Available data from early phase clinical trials indicate oral bioavailability with variable systemic exposure. Metabolism is primarily hepatic, involving cytochrome P450 enzymes, with renal excretion contributing to drug clearance. However, detailed ADME profiles remain under continued study to establish comprehensive pharmacokinetic characterizations.
Safety and toxicity assessments are ongoing, with attention to dose-limiting toxicities typical for PARP inhibitors such as hematological adverse effects, including anemia, neutropenia, and thrombocytopenia. Further evaluation of its safety profile and risk-benefit ratio is essential before regulatory approval.
Veliparib is currently undergoing clinical evaluation and has not received marketing authorization. It is not marketed under established brand names.
For API procurement, attention to chemical purity, stereochemical integrity, and compliance with Good Manufacturing Practice (GMP) standards is critical. Reliable sourcing requires documentation of synthetic route reproducibility and impurity profiling, given the investigational status and the compound’s therapeutic context.
Identification & chemistry
| Generic name | Veliparib |
|---|---|
| Molecule type | Small molecule |
| CAS | 912444-00-9 |
| UNII | 01O4K0631N |
| DrugBank ID | DB07232 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Poly [ADP-ribose] polymerase 1 | Humans | |
| Poly [ADP-ribose] polymerase 2 | Humans |
Formulation & handling
- Veliparib is a small molecule suitable for oral formulation due to its solid state and moderate water solubility.
- Its low LogP indicates balanced hydrophilicity and lipophilicity, facilitating absorption but necessitating consideration of solubility enhancement techniques.
- Handling requires standard precautions for investigational benzimidazole compounds, with no specific peptide or biologic stability concerns.
Regulatory status
Veliparib is a type of Protein kinase inhibitors
Protein kinase inhibitors are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in targeted cancer therapies. These inhibitors specifically target and block the activity of protein kinases, enzymes that regulate various cellular processes, including cell growth, division, and signal transduction.
Protein kinase inhibitors function by binding to the active site of protein kinases, preventing them from phosphorylating specific proteins and disrupting intracellular signaling pathways. This targeted approach inhibits the uncontrolled growth and proliferation of cancer cells, ultimately leading to their death.
The development of protein kinase inhibitors has revolutionized cancer treatment by providing more effective and less toxic alternatives to traditional chemotherapy. These drugs have demonstrated impressive results in the treatment of various cancers, including lung, breast, and leukemia.
The pharmaceutical industry invests heavily in research and development to discover novel protein kinase inhibitors with improved potency, selectivity, and pharmacokinetic properties. High-throughput screening, computational modeling, and structure-activity relationship studies are employed to identify potential lead compounds.
The success of protein kinase inhibitors in treating cancer has spurred significant interest in this subcategory of APIs. Ongoing research aims to expand their applications to other diseases, such as autoimmune disorders and neurological conditions.
In conclusion, protein kinase inhibitors are a valuable class of pharmaceutical APIs with immense potential for targeted cancer therapies. Continued advancements in this field hold promise for improved treatment outcomes and enhanced patient care.
Veliparib (Protein kinase inhibitors), classified under Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
